Zobrazeno 1 - 10
of 764
pro vyhledávání: '"Elihu H. Estey"'
Autor:
John J. Lim, Megan Othus, Carole M. Shaw, Kathryn Russell, Anna B. Halpern, Jacob S. Appelbaum, Paul Hendrie, Roland B. Walter, Elihu H. Estey, Mary-Elizabeth M. Percival
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-4 (2024)
Externí odkaz:
https://doaj.org/article/845027fb887844a09bcecd5251187282
Autor:
Megan Othus, Guillermo Garcia-Manero, John E. Godwin, James K. Weick, Frederick R. Appelbaum, Harry P. Erba, Elihu H. Estey
Publikováno v:
Haematologica, Vol 108, Iss 1 (2022)
We have previously shown that complete response (CR) rates and overall survival of patients with acute myeloid leukemia have improved since the 1980s. However, we have not previously evaluated how the length of first CR (CR1) has changed over this ti
Externí odkaz:
https://doaj.org/article/de1cfaf03ff2478e8cfd157adae95ad7
Autor:
Jorge E. Cortes, Marcos de Lima, Hervé Dombret, Elihu H. Estey, Sergio A. Giralt, Pau Montesinos, Christoph Röllig, Adriano Venditti, Eunice S. Wang
Publikováno v:
Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-8 (2020)
Abstract Gemtuzumab ozogamicin (GO), a humanized anti-CD33 monoclonal antibody conjugated to the cytotoxic antibiotic agent calicheamicin, is approved for the treatment of newly-diagnosed CD33 + AML in adults and children ≥ 1 month old, and relapse
Externí odkaz:
https://doaj.org/article/389f883efb66456f8cfaa6345ac27639
Autor:
Mohamed L. Sorror, Shirali Agarwal, Megan Othus, Ylinne Lynch, Jennifer E. Nyland, Mary‐Elizabeth Percival, Pamela S. Becker, Frederick R. Appelbaum, Elihu H. Estey
Publikováno v:
Cancer Medicine, Vol 9, Iss 18, Pp 6515-6523 (2020)
Abstract Background Low‐intensity regimens have been increasingly used to treat older patients with acute myeloid leukemia (AML). Recent studies, however, suggest older patients can tolerate and potentially benefit from intensive chemotherapeutic r
Externí odkaz:
https://doaj.org/article/a55df821182943a69f00be2393140f0f
Autor:
Colin D. Godwin, Eduardo Rodríguez-Arbolí, Megan Othus, Anna B. Halpern, Jacob S. Appelbaum, Mary-Elizabeth M. Percival, Paul C. Hendrie, Vivian G. Oehler, Siobán B. Keel, Janis L. Abkowitz, Jason P. Cooper, Ryan D. Cassaday, Elihu H. Estey, Roland B. Walter
Publikováno v:
Cancers, Vol 14, Iss 12, p 2934 (2022)
Gemtuzumab ozogamicin (GO) improves outcomes when added to intensive AML chemotherapy. A meta-analysis suggested the greatest benefit when combining fractionated doses of GO (GO3) with 7 + 3. To test whether GO3 can be safely used with high intensity
Externí odkaz:
https://doaj.org/article/5ecb8885b7d247339f2c1d0b2022140f
Autor:
Mary-Elizabeth M. Percival, Megan Othus, Sarah Mirahsani, Kelda M. Gardner, Carole Shaw, Anna B. Halpern, Pamela S. Becker, Paul C. Hendrie, Mohamed L. Sorror, Roland B. Walter, Elihu H. Estey
Publikováno v:
Haematologica, Vol 106, Iss 8 (2020)
Few patients with cancer, including those with acute myeloid leukemia and high-grade myeloid neoplasms, participate in clinical trials. Broadening standard eligibility criteria may increase clinical trial participation. In this retrospective single-c
Externí odkaz:
https://doaj.org/article/0395b57df88646eda61744ee5d03ecfc
Autor:
Sabine Kayser, Robert K. Hills, Marlise R. Luskin, Andrew M. Brunner, Christine Terré, Jörg Westermann, Kamal Menghrajani, Carole Shaw, Maria R. Baer, Michelle A. Elliott, Alexander E. Perl, Zdeněk Ráčil, Jiri Mayer, Pavel Zak, Tomas Szotkowski, Stéphane de Botton, David Grimwade, Karin Mayer, Roland B. Walter, Alwin Krämer, Alan K. Burnett, Anthony D. Ho, Uwe Platzbecker, Christian Thiede, Gerhard Ehninger, Richard M. Stone, Christoph Röllig, Martin S. Tallman, Elihu H. Estey, Carsten Müller-Tidow, Nigel H. Russell, Richard F. Schlenk, Mark J. Levis
Publikováno v:
Haematologica, Vol 105, Iss 1 (2020)
Acute myeloid leukemia (AML) with t(6;9)(p22;q34) is a distinct entity accounting for 1-2% of AML cases. A substantial proportion of these patients have a concomitant FLT3-ITD. While outcomes are dismal with intensive chemotherapy, limited evidence s
Externí odkaz:
https://doaj.org/article/0f6f067246d842ec9f1f02982bdc9c76
Autor:
Su-In Lee, Safiye Celik, Benjamin A. Logsdon, Scott M. Lundberg, Timothy J. Martins, Vivian G. Oehler, Elihu H. Estey, Chris P. Miller, Sylvia Chien, Jin Dai, Akanksha Saxena, C. Anthony Blau, Pamela S. Becker
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-13 (2018)
Identification of markers of drug response is essential for precision therapy. Here the authors introduce an algorithm that uses prior information about each gene’s importance in AML to identify the most predictive gene-drug associations from trans
Externí odkaz:
https://doaj.org/article/ff277a1927e34d3491a2ec37c88816b8
Autor:
Anna B. Halpern, Megan Othus, Emily M. Huebner, Bart L. Scott, Paul C. Hendrie, Mary-Elizabeth M. Percival, Pamela S. Becker, Heather A. Smith, Vivian G. Oehler, Johnnie J. Orozco, Ryan D. Cassaday, Kelda M. Gardner, Tara L. Chen, Sarah A. Buckley, Kaysey F. Orlowski, Asma Anwar, Elihu H. Estey, Roland B. Walter
Publikováno v:
Haematologica, Vol 104, Iss 4 (2019)
Externí odkaz:
https://doaj.org/article/f4c60eaa187e447a9c5cf66831e4bbbf
Autor:
Roland B. Walter, Megan Othus, Kaysey F. Orlowski, Emily N. McDaniel, Bart L. Scott, Pamela S. Becker, Mary-Elizabeth M. Percival, Paul C. Hendrie, Bruno C. Medeiros, Michael T. Chiarella, Arthur C. Louie, Elihu H. Estey
Publikováno v:
Haematologica, Vol 103, Iss 3 (2018)
Externí odkaz:
https://doaj.org/article/b050983645dc49d4893f684b474b0d2c